RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 93 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2013. The put-call ratio across all filers is 13.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $893,000 | -36.6% | 375,264 | -2.2% | 0.00% | 0.0% |
Q3 2016 | $1,408,000 | +48.4% | 383,690 | -9.8% | 0.00% | 0.0% |
Q2 2016 | $949,000 | +7.5% | 425,410 | +0.2% | 0.00% | 0.0% |
Q1 2016 | $883,000 | -29.5% | 424,427 | +2.7% | 0.00% | 0.0% |
Q4 2015 | $1,252,000 | +7.5% | 413,126 | -12.4% | 0.00% | 0.0% |
Q3 2015 | $1,165,000 | -16.2% | 471,584 | +8.9% | 0.00% | 0.0% |
Q2 2015 | $1,390,000 | -28.9% | 432,979 | -21.0% | 0.00% | -50.0% |
Q1 2015 | $1,955,000 | +57.8% | 547,753 | +0.3% | 0.00% | +100.0% |
Q4 2014 | $1,239,000 | -37.8% | 545,864 | -46.8% | 0.00% | -50.0% |
Q3 2014 | $1,992,000 | -46.0% | 1,026,590 | +1.1% | 0.00% | -33.3% |
Q2 2014 | $3,686,000 | +136.6% | 1,015,346 | +152.8% | 0.00% | +50.0% |
Q1 2014 | $1,558,000 | +821.9% | 401,666 | +578.5% | 0.00% | – |
Q4 2013 | $169,000 | -11.1% | 59,201 | +11.5% | 0.00% | – |
Q3 2013 | $190,000 | +7.3% | 53,106 | +0.4% | 0.00% | – |
Q2 2013 | $177,000 | – | 52,873 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |